to the South African guidelines for inclusion in this program as depicted in Patients referred to this clinic came with the CD4 count as baseline.
Procedures and follow-up Investigators (medical doctors, nurses, psychologists, social workers) had experience treating HIV-infected persons. Data were abstracted from the database and patient's charts from July 2004 to December 2006 (30 months) at each monthly visit and entered electronically by trained medical doctors and then compiled centrally and reviewed and edited before being analyzed.
Data collected included age, sex, baseline CD4-counts, date of starting ART, date of death, treatment regimen give, the date of last visit or lost of review, the date of transfer out, and the cause of death. We analyzed all deaths, including those not directly due to AIDS or indirectly from conditions exacerbated by HIV-infection (such as hepatic, renal, or cardiac disease).
screening
The HIV Combi Immunoassay for the in vitro determination of HIV-p24 antigen and antibodies to HIV-1, including group O, and HIV-2 in human serum and plasma was used for screening with Elecsys 2010 modular analytics E170 machine (Roche Products, Basel, Switzerland and Hitachi High-Technologies Coporation, Tokyo Japan). The sensitivity of the Elecsys HIV Combi assay is 100%. The 95% lower confidence limit is 99.80%. The specificity of the Elecsys HIV Combi is 99.63%, and the 95% lower confidence limit was found to be 99.42%. Samples that tested positive with the Elecsys HIV Combi were confirmed using AxSYM® HIV Ag/Ab Combo using Abbot Axsym Automated Immunoassay Analyzer (Abbot Laboratories, Donegal/Chicago, USA). AxSYM HIV Ag/Ab Combo is a microparticle enzyme immunoassay for simultaneous qualitative detection of antibodies to human they are already sick, to medical care due to stigma. The lack of resources lead to long waiting lists, which is for months and therefore the CD4-count drop down to very low levels before the treatment is started. The patients in our South African population are admitted in the general wards with severe opportunistic infections, HIV related diseases, and from other unrelated causes.
8 The Department of Health in South Africa started supplying ART to HIV-infected persons later than many countries in the world, precisely since 2004. Despite this ART introduction, it is still very difficult to put such patients on ART as the compliance cannot be assessed because of the condition of the patient and lack of knowledge of their background. Furthermore, data show significant higher morbidity and mortality reported after ART introduction in some resource poor countries 10 , these are lacking in South Africa. To avoid such early mortality in HIV/AIDS patients, we need to identify its predictors and mobilize to prevent and eliminate them. This requires availability of more information like that obtained by this study. We evaluated mortality rates according to etiology, demographic parameters, CD4-counts, and ART regimen among South African HIV/AIDS patients.
PAtIEnts And mEthods design and setting
This was a prospective observational ongoing study which is part of monitoring of all the patients treated with antiretroviral drugs among adult HIV/AIDS patients admitted to Tshepang clinic at Doctor George Mukhari Hospital (DGMH), Pretoria, South Africa. DGMH is a 1700-bed tertiary health institution in Gauteng. It receives referrals from part of Gauteng Province, North West, Limpopo, and part of Mpumalanga Province. Tshepang clinic is the site accredited to supply ART in this hospital. This clinic receives HIV/AIDS patients referred from primary health care centers, general practitioners, and regional hospitals from the provinces mentioned above. Some of the patients are self referrals. study population Patients considered were all patients who were enrolled on ART conforming The patients were encouraged to use injectable contraceptives. If unable to guarantee reliable contraception, Nevarapine was substituted for Efavirance. Deaths were identified directly from patient's records and social worker's reports.
statistical analysis Age was presented as mean standard deviation while categorical variables were presented as percentages (proportions). The Student t-test or χ 2 test procedures were used to assess the univariate associations between age or categorical variables and mortality. All analyses were performed with a p-value set at <0.05 (significant) using SPSS software version 14.0 for Windows (SPSS, Chicago, IL, USA).
rEsuLts Out of 3073 patients included, 1002 were males, 2071 were females, 2924 were on regimen 1a, 82 were on regimen 1b, 29 were on regimen 2,434 were lost of view, and 34 were transfers out. Therefore, out of the analyzed population, 2605 patients (response rate: 84.8%), a total of 204 individuals (7.8%) died during the follow-up. There were 3.3 deaths/100 years between 2004 and 2006.
underlying causes of mortality
The causes of these 204 deaths were dominated by opportunistic infections (42.7%, n = 87: 42 cases of tuberculosis, 25 cases of chronic diarrhea, 18 cases of Cryptococcus meningitis infection, and 12 cases of bacterial pneumonia/pneumocystis pneumonia) and advanced AIDS (37.3% n = 76), whereas HIV/AIDS -related cancers represented 8.3% of deaths (11 cases of Kaposi Sarcoma, and 6 cases of lymphoma). Other causes of death were hepatitis (n = 6) and stroke (n = 3).
The most frequently reported opportunistic infections among infectious causes of deaths were tuberculosis (48.3%) in comparison with other opportunistic infections.
There was no patient who died of non-AIDS malignancies, but 12 cases with lactic acidosis (ART-related complications).
deaths and time of Art Although 95% of deaths occurred during the first year of ART, there was a significant decrease (p for linear trend <0.0001) of mortality rates over the period of ART for these HIV-infected patients (FIGurE 2). deaths and demographic characteristics There was not a significant association between age groups and mortality rates (results not shown). However, sex was only reported for 2176 patients whose 689 (31.7%) were males and 1487 (68.3%) females. The mortality rate was higher (p <0.0001) in males (28%, n = 193) than females (8%, n = 119). Sensitivity of HIV-1 antibody detection rate in a population of 615 HIV-1 antibody confirmed seropositive individuals is 100% (615/615). This rate includes 453 clinically diagnosed patients from different disease stages of HIV-1 infection and 55 HIV-1 subtyped sample. HIV-2 antibody detection rate in a population of 108 HIV-2 antibody confirmed seropositive individuals is 100% (108/108). HIV p24 antigen detection rate in a defined (≥25 pg/µl) population of 50 HIV p24 antigen confirmed positive individuals is 100% (50/50). HIV-1 group 0 antibody detection rate in a population of 19 HIV-1 group 0 antibody confirmed positive specimens tested is 100% (19/19).
CD4 cell counts have been measured using Flow Cytometry Epics XL-MCL (Beckman Coulter, Miami, Florida, USA).
operational definitions Advanced HIV/AIDS disease was defined by the WHO stage III/IV disease. HAART was defined as at least triple therapy including 2 nucleoside reverse transcriptase inhibitors (NRTI: 1a regimen) plus at least 1 protease inhibitor or 1 non-nucleoside reverse transcriptase inhibitor (1b regimen) or a 3rd NRTI (2 regimen). Criteria for initiation or maintenance of HAART were based on the updated recommendations existing at the time of this study. Antiretroviral therapy could be modified at the discretion of the treating physician. All the patients remained in the study as long as they remained on HAART till the end of the study. risk of dying during the first year of Art The absolute risk (probability) of dying during the first year of ART in this study was estimated 95% and 8-fold more elevated than that of 11.7% reported in Senegal. 10 This highest mortality during the 1st year of ART attenuates the benefits of ART on overall mortality and raises the problem of appropriate and specific guidelines of HIV/AIDS management in South Africa. Highest proportions of advanced AIDS disease and Tuberculosis and lowest levels of CD4-counts may explain this highest probability of dying.
10 Efforts towards an earlier initiation of ART in African HIV/AIDS patients and a better approach to avoid late diagnosis of HIV-infection as well to diagnosis and management of tuberculosis, opportunistic infections, and malnutrition will be the next step to limit the still too high mortality during the first year of ART.
This study suggests that more research is needed on the threshold of CD4-counts to initiate ART in Africans. CD4-counts <200/µl, identified with higher probability of dying in this study, should be the cut-off point to start any ART regimen. Indeed, not only mortality did not vary with ART regimens, no side effects related to ART were reported in this study. Furthermore male sex appeared to affect prognosis (28% vs. 8% mortality in females) more markedly than CD4-counts <200/ml and age. This study is the only to report a significant association between mortality and sex in HIV/AIDS patients. Indeed, SSA including South Africa has one of the highest prevalences of HIV/AIDS as well as the highest AIDS-related mortality in the world. [7] [8] [9] We conducted this study because measuring the impact of HIV disease and its treatment on mortality is the key to developing and assessing the impact of programmes to mitigate the effects of the HIV pandemic at global, regional and national levels in our country South Africa in particular). Major findings of the present study are discussed below.
Potent antiretroviral therapy This study showed that total mortality has decreased substantially among these HIV/AIDS patients with access to ART as reported in developed countries 1-6 and another SSA country such as Senegal 10 . Before the era of ART, crude mortality rates were 18.3% in South Africa 8 and 35% in Kenya 9 . Thus HIV/AIDS related mortality has been reduced 2-4 time (7.8%) by ART in this study in comparison with mortality rates from previous African studies. 8, 9 The mortality rates in ART-treated HIV-infected at the first experience of initiation of HAART era in developed countries (7 deaths/100 per years in 1996) 11 and Senegal (6.3 deaths/100 person-years in 1998) concLusIons Mortality in HIV/AIDS patients receiving ART has decreased since 2004 with the routine introduction of ART in South Africa. Despite the lethal 1st year of ART administration, mortality decreased over follow-up time. CD4-counts <200/µl and male sex are significantly associated with higher mortality. Tuberculosis and advanced AIDS are the main underlying causes of death. 
